SlideShare a Scribd company logo
1 of 4
Download to read offline
REAL-TIME
REAL-WORLD
SEE THE REAL-WORLD
IMPACT FOR YOURSELF.
WE DON’T
JUST TALK
ABOUT DATA.
WE SHOW
RESULTS.
A DIRECT CONNECTION TO FINDING POTENTIAL
CLINICAL TRIAL PARTICIPANTS
CLIENT CHALLENGE
CLIENT CHALLENGE
REAL-WORLD IMPACT
REAL-WORLD IMPACT
Month 1 Results: 4,829 patients emailed, 523 visited the study website, 7 consented, 6 completed
Patient Service Center (PSC) blood draws
Difficulty recruiting
patients for a virtual
study with a PSC
blood draw
Extremely tight
turnaround times
for launching email
campaigns and
boosting recruitment
PROTOCOL DESIGN TO MAXIMIZE
PATIENT ENROLLMENT OPPORTUNITY
Result: The eligible patient population increased by +50% without compromising the objectives of the trial.
Analyzed LabCorp de-identified
clinical laboratory data to discern
whether small protocol changes
could accelerate recruitment.
Data helped to identify that
making minor changes to the
eGFR cutoff would increase
the patient pool size, therefore
reducing recruitment timelines.
Study to test if a drug
reduced progression of
kidney disease in patients
with Type II diabetes
Study was looking for a
small subset of patients
which represented
<7% of patients
Leveraged LabCorp
database to find potential
patients in key geographies
as specified by the client.
LabCorp sent emails with
study specific website
links to targeted patient
populations.
Seeking patients with
a history of stroke or
cardiovascular event
~150 Million
Lives
>150
million patients
>30
billion test results
>
INCORPORATING THE PATIENT VOICE
CLIENT CHALLENGE
CLIENT CHALLENGE REAL-WORLD IMPACT
REAL-WORLD IMPACT
Result: Conducted research with 320 Ulcerative Colitis patients to design a study to meet the client’s
needs. Extended the known investigator database for Ulcerative Colitis with available capacity.
Leveraged Covance Patient
Intelligence Database to
improve patient recruitment
and retention rates.
Identified investigator best-
suited to run Ulcerative
Colitis studies with available
capacity.
Limited patient population
due to competing studies
and the fact that 90% of
patients don’t participate
in clinical trials
Difficulty finding, productive
investigators for study in a
highly competitive space
EXCEEDING RECRUITMENT GOALS FOR A
GLOBAL MULTI-STUDY REGISTRATION PROGRAM
Result: Achieved “first patient in” (FPI) requirement ahead of schedule for all studies in the program.
Beat historical industry performance across a number of key metrics:
18% fewer weeks from final protocol to FPI | 75% more high-performing sites
31% more patients/site/month | 41% fewer non-performing sites
Randomize 2,700
patients within a very
narrow timeframe for
a suite of registration
studies
Get all sites across
the globe up and
running as quickly
as possible
Leveraged Xcellerate®
historical investigator
database to identify and
secure highest performing
investigators in indication.
Based on extensive feasibility
outreach and site capacity
assessment, efficiencies
were identified that allowed
effective overlapping of sites
across the program resulting in
accelerated site start-up and
reduced clinical costs.
90%
~30countries
>20
indications
>175k
unique investigators
>15k
protocols
*Average time savings based on an analysis of trials processed through Covance Central Labs with Protocol
Finalization date after 1/1/2009 for the specific clinical indications. Past performance is not a guarantee of
future results, and a variety of factors other than CRO performance can impact timing of clinical studies.
Covance is the drug, medical device and diagnostics
business segment of LabCorp, a leading global
life sciences company. COVANCE is a registered
trademark and the marketing name for Covance Inc.
and its subsidiaries around the world.
The Americas +1.888.COVANCE (+1.888.268.2623)
+1.609.452.4440
Europe/Africa +00.800.2682.2682
+44.1423.500888
Asia Pacific +800.6568.3000 +65.6.5686588
© Copyright 2019 Covance Inc. BROCVD018-1019
REAL-TIME DATA. REAL-WORLD IMPACT.
Talk to a representative to find out how Covance can impact your studies.
LEARN MORE AT COVANCE.COM/REALIMPACT
COVANCE DATA CAN HELP ACCELERATE YOUR STUDIES.
Covance data is comprised of four powerful data sets: LabCorp De-Identified Lab Result Data,
Covance Central Labs Investigator Data, Patient Direct and Patient Intelligence. The combination of
these data sets provides unique insights, enabling us to deliver strong, viable protocol designs for
faster patient enrollment, more patients per site and fewer non-performing sites than the industry
average. By increasing forecast accuracy, you can minimize study costs and speed time to market.
SITE ACTIVATION TO LAST PATIENT IN
Number of Months*
MONTHS
FASTER
CARDIOVASCULAR3.1 MARKET
12.92
MONTHS
COVANCE
9.85
MONTHS
5.0
MARKET
14.88
MONTHS
COVANCE
9.94
MONTHS
MONTHS
FASTER
NEUROLOGY
3.3 MARKET
18.66
MONTHS
COVANCE
15.41
MONTHS
MONTHS
FASTER
HEMATOLOGY
4.2 MARKET
20.99
MONTHS
COVANCE
16.80
MONTHS
MONTHS
FASTER
ONCOLOGY

More Related Content

What's hot

Transparency Life Sciences
Transparency Life SciencesTransparency Life Sciences
Transparency Life SciencesDayOne
 
Patient Centricity: EHR Pillars to Patient Centricity
Patient Centricity: EHR Pillars to Patient CentricityPatient Centricity: EHR Pillars to Patient Centricity
Patient Centricity: EHR Pillars to Patient CentricityDayOne
 
Next Generation Digital Trials - Introduction to a changing landscape
Next Generation Digital Trials - Introduction to a changing landscape Next Generation Digital Trials - Introduction to a changing landscape
Next Generation Digital Trials - Introduction to a changing landscape DayOne
 
eLabels Initiative - eLabels Toolkit v2.0
eLabels Initiative - eLabels Toolkit v2.0eLabels Initiative - eLabels Toolkit v2.0
eLabels Initiative - eLabels Toolkit v2.0TransCelerate
 
Paul Coplan, VP, Johnson & Johnson_mHealth Israel
Paul Coplan, VP, Johnson & Johnson_mHealth IsraelPaul Coplan, VP, Johnson & Johnson_mHealth Israel
Paul Coplan, VP, Johnson & Johnson_mHealth IsraelLevi Shapiro
 
Real-Time Data. Real-World Impact. Infographic
Real-Time Data. Real-World Impact. InfographicReal-Time Data. Real-World Impact. Infographic
Real-Time Data. Real-World Impact. InfographicCovance
 
AGREE II Instrument: Assessment of the Quality of Clinical Practice Guidelines
AGREE II Instrument: Assessment of the Quality of Clinical Practice Guidelines AGREE II Instrument: Assessment of the Quality of Clinical Practice Guidelines
AGREE II Instrument: Assessment of the Quality of Clinical Practice Guidelines Yasser Sami Abdel Dayem Amer
 
Ronan Herlihy on Engaging Clinicians with data on their ordering practices
Ronan Herlihy on Engaging Clinicians with data on their ordering practicesRonan Herlihy on Engaging Clinicians with data on their ordering practices
Ronan Herlihy on Engaging Clinicians with data on their ordering practicesCirdan
 
Racing for results: lessons learnt in improving the efficiency of HIV VL and ...
Racing for results: lessons learnt in improving the efficiency of HIV VL and ...Racing for results: lessons learnt in improving the efficiency of HIV VL and ...
Racing for results: lessons learnt in improving the efficiency of HIV VL and ...SystemOne
 
Digital Scholar Webinar: Breaking Down (Brick) Walls: Switching to Remote, Vi...
Digital Scholar Webinar: Breaking Down (Brick) Walls: Switching to Remote, Vi...Digital Scholar Webinar: Breaking Down (Brick) Walls: Switching to Remote, Vi...
Digital Scholar Webinar: Breaking Down (Brick) Walls: Switching to Remote, Vi...SC CTSI at USC and CHLA
 
Real-World Data – What’s Next? by Michael Seewald, AstraZeneca for mHealth Is...
Real-World Data – What’s Next? by Michael Seewald, AstraZeneca for mHealth Is...Real-World Data – What’s Next? by Michael Seewald, AstraZeneca for mHealth Is...
Real-World Data – What’s Next? by Michael Seewald, AstraZeneca for mHealth Is...Levi Shapiro
 
mHealth Israel_Growth Opportunities in Clinical Trial Execution_Craig Lipset
mHealth Israel_Growth Opportunities in Clinical Trial Execution_Craig LipsetmHealth Israel_Growth Opportunities in Clinical Trial Execution_Craig Lipset
mHealth Israel_Growth Opportunities in Clinical Trial Execution_Craig LipsetLevi Shapiro
 
Real-Time Data. Real-World Impact Brochure
Real-Time Data. Real-World Impact Brochure Real-Time Data. Real-World Impact Brochure
Real-Time Data. Real-World Impact Brochure Covance
 
The power of information: Achieving a national infection management system
The power of information: Achieving a national infection management systemThe power of information: Achieving a national infection management system
The power of information: Achieving a national infection management systemHealth Informatics New Zealand
 
Rheumatoid Arthritis Treatment Landscape
Rheumatoid Arthritis Treatment Landscape Rheumatoid Arthritis Treatment Landscape
Rheumatoid Arthritis Treatment Landscape Covance
 
Aldo Rolfo, National Clinical Development Manager, Genesis Cancer Care, Austr...
Aldo Rolfo, National Clinical Development Manager, Genesis Cancer Care, Austr...Aldo Rolfo, National Clinical Development Manager, Genesis Cancer Care, Austr...
Aldo Rolfo, National Clinical Development Manager, Genesis Cancer Care, Austr...GenesisCareUK
 
Getting Right with The Joint Commission's Communication Goal
Getting Right with The Joint Commission's Communication GoalGetting Right with The Joint Commission's Communication Goal
Getting Right with The Joint Commission's Communication GoalSpok
 
What's Next in RWE_Amy Rudolph_Novartis_mHealth Israel
What's Next in RWE_Amy Rudolph_Novartis_mHealth IsraelWhat's Next in RWE_Amy Rudolph_Novartis_mHealth Israel
What's Next in RWE_Amy Rudolph_Novartis_mHealth IsraelLevi Shapiro
 
Primary care-based, teleretinal-screening protocol (Los Angeles Safety Net)
Primary care-based, teleretinal-screening protocol (Los Angeles Safety Net) Primary care-based, teleretinal-screening protocol (Los Angeles Safety Net)
Primary care-based, teleretinal-screening protocol (Los Angeles Safety Net) UCLA CTSI
 
Safety, Sleuthing and Students: A Novel Collaborative MedRec Event
Safety, Sleuthing and Students: A Novel Collaborative MedRec EventSafety, Sleuthing and Students: A Novel Collaborative MedRec Event
Safety, Sleuthing and Students: A Novel Collaborative MedRec EventCanadian Patient Safety Institute
 

What's hot (20)

Transparency Life Sciences
Transparency Life SciencesTransparency Life Sciences
Transparency Life Sciences
 
Patient Centricity: EHR Pillars to Patient Centricity
Patient Centricity: EHR Pillars to Patient CentricityPatient Centricity: EHR Pillars to Patient Centricity
Patient Centricity: EHR Pillars to Patient Centricity
 
Next Generation Digital Trials - Introduction to a changing landscape
Next Generation Digital Trials - Introduction to a changing landscape Next Generation Digital Trials - Introduction to a changing landscape
Next Generation Digital Trials - Introduction to a changing landscape
 
eLabels Initiative - eLabels Toolkit v2.0
eLabels Initiative - eLabels Toolkit v2.0eLabels Initiative - eLabels Toolkit v2.0
eLabels Initiative - eLabels Toolkit v2.0
 
Paul Coplan, VP, Johnson & Johnson_mHealth Israel
Paul Coplan, VP, Johnson & Johnson_mHealth IsraelPaul Coplan, VP, Johnson & Johnson_mHealth Israel
Paul Coplan, VP, Johnson & Johnson_mHealth Israel
 
Real-Time Data. Real-World Impact. Infographic
Real-Time Data. Real-World Impact. InfographicReal-Time Data. Real-World Impact. Infographic
Real-Time Data. Real-World Impact. Infographic
 
AGREE II Instrument: Assessment of the Quality of Clinical Practice Guidelines
AGREE II Instrument: Assessment of the Quality of Clinical Practice Guidelines AGREE II Instrument: Assessment of the Quality of Clinical Practice Guidelines
AGREE II Instrument: Assessment of the Quality of Clinical Practice Guidelines
 
Ronan Herlihy on Engaging Clinicians with data on their ordering practices
Ronan Herlihy on Engaging Clinicians with data on their ordering practicesRonan Herlihy on Engaging Clinicians with data on their ordering practices
Ronan Herlihy on Engaging Clinicians with data on their ordering practices
 
Racing for results: lessons learnt in improving the efficiency of HIV VL and ...
Racing for results: lessons learnt in improving the efficiency of HIV VL and ...Racing for results: lessons learnt in improving the efficiency of HIV VL and ...
Racing for results: lessons learnt in improving the efficiency of HIV VL and ...
 
Digital Scholar Webinar: Breaking Down (Brick) Walls: Switching to Remote, Vi...
Digital Scholar Webinar: Breaking Down (Brick) Walls: Switching to Remote, Vi...Digital Scholar Webinar: Breaking Down (Brick) Walls: Switching to Remote, Vi...
Digital Scholar Webinar: Breaking Down (Brick) Walls: Switching to Remote, Vi...
 
Real-World Data – What’s Next? by Michael Seewald, AstraZeneca for mHealth Is...
Real-World Data – What’s Next? by Michael Seewald, AstraZeneca for mHealth Is...Real-World Data – What’s Next? by Michael Seewald, AstraZeneca for mHealth Is...
Real-World Data – What’s Next? by Michael Seewald, AstraZeneca for mHealth Is...
 
mHealth Israel_Growth Opportunities in Clinical Trial Execution_Craig Lipset
mHealth Israel_Growth Opportunities in Clinical Trial Execution_Craig LipsetmHealth Israel_Growth Opportunities in Clinical Trial Execution_Craig Lipset
mHealth Israel_Growth Opportunities in Clinical Trial Execution_Craig Lipset
 
Real-Time Data. Real-World Impact Brochure
Real-Time Data. Real-World Impact Brochure Real-Time Data. Real-World Impact Brochure
Real-Time Data. Real-World Impact Brochure
 
The power of information: Achieving a national infection management system
The power of information: Achieving a national infection management systemThe power of information: Achieving a national infection management system
The power of information: Achieving a national infection management system
 
Rheumatoid Arthritis Treatment Landscape
Rheumatoid Arthritis Treatment Landscape Rheumatoid Arthritis Treatment Landscape
Rheumatoid Arthritis Treatment Landscape
 
Aldo Rolfo, National Clinical Development Manager, Genesis Cancer Care, Austr...
Aldo Rolfo, National Clinical Development Manager, Genesis Cancer Care, Austr...Aldo Rolfo, National Clinical Development Manager, Genesis Cancer Care, Austr...
Aldo Rolfo, National Clinical Development Manager, Genesis Cancer Care, Austr...
 
Getting Right with The Joint Commission's Communication Goal
Getting Right with The Joint Commission's Communication GoalGetting Right with The Joint Commission's Communication Goal
Getting Right with The Joint Commission's Communication Goal
 
What's Next in RWE_Amy Rudolph_Novartis_mHealth Israel
What's Next in RWE_Amy Rudolph_Novartis_mHealth IsraelWhat's Next in RWE_Amy Rudolph_Novartis_mHealth Israel
What's Next in RWE_Amy Rudolph_Novartis_mHealth Israel
 
Primary care-based, teleretinal-screening protocol (Los Angeles Safety Net)
Primary care-based, teleretinal-screening protocol (Los Angeles Safety Net) Primary care-based, teleretinal-screening protocol (Los Angeles Safety Net)
Primary care-based, teleretinal-screening protocol (Los Angeles Safety Net)
 
Safety, Sleuthing and Students: A Novel Collaborative MedRec Event
Safety, Sleuthing and Students: A Novel Collaborative MedRec EventSafety, Sleuthing and Students: A Novel Collaborative MedRec Event
Safety, Sleuthing and Students: A Novel Collaborative MedRec Event
 

Similar to Real-Time Data. Real-World Impact.

Customized Oncology Development Solutions: Clinical Trials Designed Around You®
Customized Oncology Development Solutions: Clinical Trials Designed Around You®Customized Oncology Development Solutions: Clinical Trials Designed Around You®
Customized Oncology Development Solutions: Clinical Trials Designed Around You®Covance
 
Solving the operational challenges of oncology clinical trials
Solving the operational challenges of oncology clinical trialsSolving the operational challenges of oncology clinical trials
Solving the operational challenges of oncology clinical trialsRoberto Lara
 
Sanguine sales deck_2015_jg_updated
Sanguine sales deck_2015_jg_updatedSanguine sales deck_2015_jg_updated
Sanguine sales deck_2015_jg_updatedCarlynSanguine
 
Putting the Oncology Patient First
Putting the Oncology Patient FirstPutting the Oncology Patient First
Putting the Oncology Patient FirstCRF Health
 
white-paper-innovation-clinical-trials
white-paper-innovation-clinical-trialswhite-paper-innovation-clinical-trials
white-paper-innovation-clinical-trialsUlrich Neumann, FRSA
 
Big data, RWE and AI in Clinical Trials made simple
Big data, RWE and AI in Clinical Trials made simpleBig data, RWE and AI in Clinical Trials made simple
Big data, RWE and AI in Clinical Trials made simpleHadas Jacoby
 
Listening to the Patient - Leveraging Direct-to-Patient Data Collection to Sh...
Listening to the Patient - Leveraging Direct-to-Patient Data Collection to Sh...Listening to the Patient - Leveraging Direct-to-Patient Data Collection to Sh...
Listening to the Patient - Leveraging Direct-to-Patient Data Collection to Sh...John Reites
 
Rheumatoid Arthritis Treatment Landscape
Rheumatoid Arthritis Treatment LandscapeRheumatoid Arthritis Treatment Landscape
Rheumatoid Arthritis Treatment LandscapeCovance
 
Challenges and Solutions in Immune-Mediated Inflammatory Disease Trials White...
Challenges and Solutions in Immune-Mediated Inflammatory Disease Trials White...Challenges and Solutions in Immune-Mediated Inflammatory Disease Trials White...
Challenges and Solutions in Immune-Mediated Inflammatory Disease Trials White...Covance
 
Build a Path to Success and Accelerate Your NASH Trials
Build a Path to Success and Accelerate Your NASH Trials Build a Path to Success and Accelerate Your NASH Trials
Build a Path to Success and Accelerate Your NASH Trials Covance
 
Exodon - Company Profile and Service Overview
Exodon - Company Profile and Service OverviewExodon - Company Profile and Service Overview
Exodon - Company Profile and Service OverviewPaul Ernest de Leon
 
Clinical Data Management Agenda
Clinical Data Management AgendaClinical Data Management Agenda
Clinical Data Management AgendaTracey Zdravkovic
 
Virtual clinical trials
Virtual clinical trialsVirtual clinical trials
Virtual clinical trialsDrSahilKumar
 
A LEAN SIX SIGMA APPROACH TO REDUCE WAITING AND REPORTING TIME IN THE RADIOLO...
A LEAN SIX SIGMA APPROACH TO REDUCE WAITING AND REPORTING TIME IN THE RADIOLO...A LEAN SIX SIGMA APPROACH TO REDUCE WAITING AND REPORTING TIME IN THE RADIOLO...
A LEAN SIX SIGMA APPROACH TO REDUCE WAITING AND REPORTING TIME IN THE RADIOLO...Joe Andelija
 
Pcori health 2.0 challenge with screenshots_patients_likeme_041513
Pcori health 2.0 challenge with screenshots_patients_likeme_041513Pcori health 2.0 challenge with screenshots_patients_likeme_041513
Pcori health 2.0 challenge with screenshots_patients_likeme_041513Sally Okun
 
Better late than never
Better late than neverBetter late than never
Better late than neverdrucsamal
 

Similar to Real-Time Data. Real-World Impact. (20)

Customized Oncology Development Solutions: Clinical Trials Designed Around You®
Customized Oncology Development Solutions: Clinical Trials Designed Around You®Customized Oncology Development Solutions: Clinical Trials Designed Around You®
Customized Oncology Development Solutions: Clinical Trials Designed Around You®
 
Solving the operational challenges of oncology clinical trials
Solving the operational challenges of oncology clinical trialsSolving the operational challenges of oncology clinical trials
Solving the operational challenges of oncology clinical trials
 
Sanguine sales deck_2015_jg_updated
Sanguine sales deck_2015_jg_updatedSanguine sales deck_2015_jg_updated
Sanguine sales deck_2015_jg_updated
 
Oncology PRA Health Sciences
Oncology PRA Health SciencesOncology PRA Health Sciences
Oncology PRA Health Sciences
 
Putting the Oncology Patient First
Putting the Oncology Patient FirstPutting the Oncology Patient First
Putting the Oncology Patient First
 
white-paper-innovation-clinical-trials
white-paper-innovation-clinical-trialswhite-paper-innovation-clinical-trials
white-paper-innovation-clinical-trials
 
Big data, RWE and AI in Clinical Trials made simple
Big data, RWE and AI in Clinical Trials made simpleBig data, RWE and AI in Clinical Trials made simple
Big data, RWE and AI in Clinical Trials made simple
 
Listening to the Patient - Leveraging Direct-to-Patient Data Collection to Sh...
Listening to the Patient - Leveraging Direct-to-Patient Data Collection to Sh...Listening to the Patient - Leveraging Direct-to-Patient Data Collection to Sh...
Listening to the Patient - Leveraging Direct-to-Patient Data Collection to Sh...
 
Spitzer datawarehouse
Spitzer datawarehouseSpitzer datawarehouse
Spitzer datawarehouse
 
Rheumatoid Arthritis Treatment Landscape
Rheumatoid Arthritis Treatment LandscapeRheumatoid Arthritis Treatment Landscape
Rheumatoid Arthritis Treatment Landscape
 
Challenges and Solutions in Immune-Mediated Inflammatory Disease Trials White...
Challenges and Solutions in Immune-Mediated Inflammatory Disease Trials White...Challenges and Solutions in Immune-Mediated Inflammatory Disease Trials White...
Challenges and Solutions in Immune-Mediated Inflammatory Disease Trials White...
 
Build a Path to Success and Accelerate Your NASH Trials
Build a Path to Success and Accelerate Your NASH Trials Build a Path to Success and Accelerate Your NASH Trials
Build a Path to Success and Accelerate Your NASH Trials
 
Exodon - Company Profile and Service Overview
Exodon - Company Profile and Service OverviewExodon - Company Profile and Service Overview
Exodon - Company Profile and Service Overview
 
Clinical Data Management Agenda
Clinical Data Management AgendaClinical Data Management Agenda
Clinical Data Management Agenda
 
MCC WEBINAR | KRIs - The Vital Few
MCC WEBINAR | KRIs - The Vital FewMCC WEBINAR | KRIs - The Vital Few
MCC WEBINAR | KRIs - The Vital Few
 
Virtual clinical trials
Virtual clinical trialsVirtual clinical trials
Virtual clinical trials
 
A LEAN SIX SIGMA APPROACH TO REDUCE WAITING AND REPORTING TIME IN THE RADIOLO...
A LEAN SIX SIGMA APPROACH TO REDUCE WAITING AND REPORTING TIME IN THE RADIOLO...A LEAN SIX SIGMA APPROACH TO REDUCE WAITING AND REPORTING TIME IN THE RADIOLO...
A LEAN SIX SIGMA APPROACH TO REDUCE WAITING AND REPORTING TIME IN THE RADIOLO...
 
Pcori health 2.0 challenge with screenshots_patients_likeme_041513
Pcori health 2.0 challenge with screenshots_patients_likeme_041513Pcori health 2.0 challenge with screenshots_patients_likeme_041513
Pcori health 2.0 challenge with screenshots_patients_likeme_041513
 
Cellscan Stanford 2016
Cellscan Stanford 2016Cellscan Stanford 2016
Cellscan Stanford 2016
 
Better late than never
Better late than neverBetter late than never
Better late than never
 

More from Covance

Accelerate Your Scientific Discovery with GlobalCODE® - A Unique Data Managem...
Accelerate Your Scientific Discovery with GlobalCODE® - A Unique Data Managem...Accelerate Your Scientific Discovery with GlobalCODE® - A Unique Data Managem...
Accelerate Your Scientific Discovery with GlobalCODE® - A Unique Data Managem...Covance
 
Genomics Solutions - Single Target to Whole Genome Analysis
Genomics Solutions - Single Target to Whole Genome AnalysisGenomics Solutions - Single Target to Whole Genome Analysis
Genomics Solutions - Single Target to Whole Genome AnalysisCovance
 
Medical Device and Diagnostics Solutions for Every Stage of Your Product's De...
Medical Device and Diagnostics Solutions for Every Stage of Your Product's De...Medical Device and Diagnostics Solutions for Every Stage of Your Product's De...
Medical Device and Diagnostics Solutions for Every Stage of Your Product's De...Covance
 
Pharmacovigilance Risk Management for Biosimilars
Pharmacovigilance Risk Management for BiosimilarsPharmacovigilance Risk Management for Biosimilars
Pharmacovigilance Risk Management for BiosimilarsCovance
 
Cell & Gene Therapy Post-Approval Solutions
Cell & Gene Therapy Post-Approval SolutionsCell & Gene Therapy Post-Approval Solutions
Cell & Gene Therapy Post-Approval SolutionsCovance
 
Cell & Gene Therapy Enterprise Solutions
Cell & Gene Therapy Enterprise SolutionsCell & Gene Therapy Enterprise Solutions
Cell & Gene Therapy Enterprise SolutionsCovance
 
Cell & Gene Therapy Clinical Development Solutions
Cell & Gene Therapy Clinical Development SolutionsCell & Gene Therapy Clinical Development Solutions
Cell & Gene Therapy Clinical Development SolutionsCovance
 
Inhalation Technology - The Future of Effective Respiratory Treatments
Inhalation Technology - The Future of Effective Respiratory TreatmentsInhalation Technology - The Future of Effective Respiratory Treatments
Inhalation Technology - The Future of Effective Respiratory TreatmentsCovance
 
Covance Laboratory FSPx Solutions
Covance Laboratory FSPx SolutionsCovance Laboratory FSPx Solutions
Covance Laboratory FSPx SolutionsCovance
 
The Challenges Associated with Evaluating the Cost Benefit of Gene Therapies ...
The Challenges Associated with Evaluating the Cost Benefit of Gene Therapies ...The Challenges Associated with Evaluating the Cost Benefit of Gene Therapies ...
The Challenges Associated with Evaluating the Cost Benefit of Gene Therapies ...Covance
 
Environmental Risk Assessment for Pharmaceutical Drugs
Environmental Risk Assessment for Pharmaceutical DrugsEnvironmental Risk Assessment for Pharmaceutical Drugs
Environmental Risk Assessment for Pharmaceutical DrugsCovance
 
Putting the Patient First: Launching a Comprehensive Patient-Centric Program
Putting the Patient First: Launching a Comprehensive Patient-Centric ProgramPutting the Patient First: Launching a Comprehensive Patient-Centric Program
Putting the Patient First: Launching a Comprehensive Patient-Centric ProgramCovance
 
Top 15 Pharma Gains an Edge in a Highly Competitive Specialty Market
Top 15 Pharma Gains an Edge in a Highly Competitive Specialty MarketTop 15 Pharma Gains an Edge in a Highly Competitive Specialty Market
Top 15 Pharma Gains an Edge in a Highly Competitive Specialty MarketCovance
 
Field Services: Providing On-Site, Field-Based Assistance to Support Customer...
Field Services: Providing On-Site, Field-Based Assistance to Support Customer...Field Services: Providing On-Site, Field-Based Assistance to Support Customer...
Field Services: Providing On-Site, Field-Based Assistance to Support Customer...Covance
 
Covance Phase IV Solutions Brochure
Covance Phase IV Solutions BrochureCovance Phase IV Solutions Brochure
Covance Phase IV Solutions BrochureCovance
 
Optimizing Each Patient's Product Access Experience
Optimizing Each Patient's Product Access ExperienceOptimizing Each Patient's Product Access Experience
Optimizing Each Patient's Product Access ExperienceCovance
 
Patient Safety Cloud Solution Brochure
Patient Safety Cloud Solution BrochurePatient Safety Cloud Solution Brochure
Patient Safety Cloud Solution BrochureCovance
 
Plant Metabolism Studies: Options for Plant Cultivation
Plant Metabolism Studies: Options for Plant CultivationPlant Metabolism Studies: Options for Plant Cultivation
Plant Metabolism Studies: Options for Plant CultivationCovance
 
Biocide Authorization Timeline
Biocide Authorization TimelineBiocide Authorization Timeline
Biocide Authorization TimelineCovance
 
K-REACH - How to Prepare for the K-REACH Legislation
K-REACH - How to Prepare for the K-REACH LegislationK-REACH - How to Prepare for the K-REACH Legislation
K-REACH - How to Prepare for the K-REACH LegislationCovance
 

More from Covance (20)

Accelerate Your Scientific Discovery with GlobalCODE® - A Unique Data Managem...
Accelerate Your Scientific Discovery with GlobalCODE® - A Unique Data Managem...Accelerate Your Scientific Discovery with GlobalCODE® - A Unique Data Managem...
Accelerate Your Scientific Discovery with GlobalCODE® - A Unique Data Managem...
 
Genomics Solutions - Single Target to Whole Genome Analysis
Genomics Solutions - Single Target to Whole Genome AnalysisGenomics Solutions - Single Target to Whole Genome Analysis
Genomics Solutions - Single Target to Whole Genome Analysis
 
Medical Device and Diagnostics Solutions for Every Stage of Your Product's De...
Medical Device and Diagnostics Solutions for Every Stage of Your Product's De...Medical Device and Diagnostics Solutions for Every Stage of Your Product's De...
Medical Device and Diagnostics Solutions for Every Stage of Your Product's De...
 
Pharmacovigilance Risk Management for Biosimilars
Pharmacovigilance Risk Management for BiosimilarsPharmacovigilance Risk Management for Biosimilars
Pharmacovigilance Risk Management for Biosimilars
 
Cell & Gene Therapy Post-Approval Solutions
Cell & Gene Therapy Post-Approval SolutionsCell & Gene Therapy Post-Approval Solutions
Cell & Gene Therapy Post-Approval Solutions
 
Cell & Gene Therapy Enterprise Solutions
Cell & Gene Therapy Enterprise SolutionsCell & Gene Therapy Enterprise Solutions
Cell & Gene Therapy Enterprise Solutions
 
Cell & Gene Therapy Clinical Development Solutions
Cell & Gene Therapy Clinical Development SolutionsCell & Gene Therapy Clinical Development Solutions
Cell & Gene Therapy Clinical Development Solutions
 
Inhalation Technology - The Future of Effective Respiratory Treatments
Inhalation Technology - The Future of Effective Respiratory TreatmentsInhalation Technology - The Future of Effective Respiratory Treatments
Inhalation Technology - The Future of Effective Respiratory Treatments
 
Covance Laboratory FSPx Solutions
Covance Laboratory FSPx SolutionsCovance Laboratory FSPx Solutions
Covance Laboratory FSPx Solutions
 
The Challenges Associated with Evaluating the Cost Benefit of Gene Therapies ...
The Challenges Associated with Evaluating the Cost Benefit of Gene Therapies ...The Challenges Associated with Evaluating the Cost Benefit of Gene Therapies ...
The Challenges Associated with Evaluating the Cost Benefit of Gene Therapies ...
 
Environmental Risk Assessment for Pharmaceutical Drugs
Environmental Risk Assessment for Pharmaceutical DrugsEnvironmental Risk Assessment for Pharmaceutical Drugs
Environmental Risk Assessment for Pharmaceutical Drugs
 
Putting the Patient First: Launching a Comprehensive Patient-Centric Program
Putting the Patient First: Launching a Comprehensive Patient-Centric ProgramPutting the Patient First: Launching a Comprehensive Patient-Centric Program
Putting the Patient First: Launching a Comprehensive Patient-Centric Program
 
Top 15 Pharma Gains an Edge in a Highly Competitive Specialty Market
Top 15 Pharma Gains an Edge in a Highly Competitive Specialty MarketTop 15 Pharma Gains an Edge in a Highly Competitive Specialty Market
Top 15 Pharma Gains an Edge in a Highly Competitive Specialty Market
 
Field Services: Providing On-Site, Field-Based Assistance to Support Customer...
Field Services: Providing On-Site, Field-Based Assistance to Support Customer...Field Services: Providing On-Site, Field-Based Assistance to Support Customer...
Field Services: Providing On-Site, Field-Based Assistance to Support Customer...
 
Covance Phase IV Solutions Brochure
Covance Phase IV Solutions BrochureCovance Phase IV Solutions Brochure
Covance Phase IV Solutions Brochure
 
Optimizing Each Patient's Product Access Experience
Optimizing Each Patient's Product Access ExperienceOptimizing Each Patient's Product Access Experience
Optimizing Each Patient's Product Access Experience
 
Patient Safety Cloud Solution Brochure
Patient Safety Cloud Solution BrochurePatient Safety Cloud Solution Brochure
Patient Safety Cloud Solution Brochure
 
Plant Metabolism Studies: Options for Plant Cultivation
Plant Metabolism Studies: Options for Plant CultivationPlant Metabolism Studies: Options for Plant Cultivation
Plant Metabolism Studies: Options for Plant Cultivation
 
Biocide Authorization Timeline
Biocide Authorization TimelineBiocide Authorization Timeline
Biocide Authorization Timeline
 
K-REACH - How to Prepare for the K-REACH Legislation
K-REACH - How to Prepare for the K-REACH LegislationK-REACH - How to Prepare for the K-REACH Legislation
K-REACH - How to Prepare for the K-REACH Legislation
 

Recently uploaded

Future Of Sample Report 2024 | Redacted Version
Future Of Sample Report 2024 | Redacted VersionFuture Of Sample Report 2024 | Redacted Version
Future Of Sample Report 2024 | Redacted VersionMintel Group
 
/:Call Girls In Indirapuram Ghaziabad ➥9990211544 Independent Best Escorts In...
/:Call Girls In Indirapuram Ghaziabad ➥9990211544 Independent Best Escorts In.../:Call Girls In Indirapuram Ghaziabad ➥9990211544 Independent Best Escorts In...
/:Call Girls In Indirapuram Ghaziabad ➥9990211544 Independent Best Escorts In...lizamodels9
 
Call Girls In Radisson Blu Hotel New Delhi Paschim Vihar ❤️8860477959 Escorts...
Call Girls In Radisson Blu Hotel New Delhi Paschim Vihar ❤️8860477959 Escorts...Call Girls In Radisson Blu Hotel New Delhi Paschim Vihar ❤️8860477959 Escorts...
Call Girls In Radisson Blu Hotel New Delhi Paschim Vihar ❤️8860477959 Escorts...lizamodels9
 
8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR
8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR
8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCRashishs7044
 
FULL ENJOY Call girls in Paharganj Delhi | 8377087607
FULL ENJOY Call girls in Paharganj Delhi | 8377087607FULL ENJOY Call girls in Paharganj Delhi | 8377087607
FULL ENJOY Call girls in Paharganj Delhi | 8377087607dollysharma2066
 
Youth Involvement in an Innovative Coconut Value Chain by Mwalimu Menza
Youth Involvement in an Innovative Coconut Value Chain by Mwalimu MenzaYouth Involvement in an Innovative Coconut Value Chain by Mwalimu Menza
Youth Involvement in an Innovative Coconut Value Chain by Mwalimu Menzaictsugar
 
8447779800, Low rate Call girls in Shivaji Enclave Delhi NCR
8447779800, Low rate Call girls in Shivaji Enclave Delhi NCR8447779800, Low rate Call girls in Shivaji Enclave Delhi NCR
8447779800, Low rate Call girls in Shivaji Enclave Delhi NCRashishs7044
 
NewBase 19 April 2024 Energy News issue - 1717 by Khaled Al Awadi.pdf
NewBase  19 April  2024  Energy News issue - 1717 by Khaled Al Awadi.pdfNewBase  19 April  2024  Energy News issue - 1717 by Khaled Al Awadi.pdf
NewBase 19 April 2024 Energy News issue - 1717 by Khaled Al Awadi.pdfKhaled Al Awadi
 
Call US-88OO1O2216 Call Girls In Mahipalpur Female Escort Service
Call US-88OO1O2216 Call Girls In Mahipalpur Female Escort ServiceCall US-88OO1O2216 Call Girls In Mahipalpur Female Escort Service
Call US-88OO1O2216 Call Girls In Mahipalpur Female Escort Servicecallgirls2057
 
BEST Call Girls In Old Faridabad ✨ 9773824855 ✨ Escorts Service In Delhi Ncr,
BEST Call Girls In Old Faridabad ✨ 9773824855 ✨ Escorts Service In Delhi Ncr,BEST Call Girls In Old Faridabad ✨ 9773824855 ✨ Escorts Service In Delhi Ncr,
BEST Call Girls In Old Faridabad ✨ 9773824855 ✨ Escorts Service In Delhi Ncr,noida100girls
 
Contemporary Economic Issues Facing the Filipino Entrepreneur (1).pptx
Contemporary Economic Issues Facing the Filipino Entrepreneur (1).pptxContemporary Economic Issues Facing the Filipino Entrepreneur (1).pptx
Contemporary Economic Issues Facing the Filipino Entrepreneur (1).pptxMarkAnthonyAurellano
 
Buy gmail accounts.pdf Buy Old Gmail Accounts
Buy gmail accounts.pdf Buy Old Gmail AccountsBuy gmail accounts.pdf Buy Old Gmail Accounts
Buy gmail accounts.pdf Buy Old Gmail AccountsBuy Verified Accounts
 
Keppel Ltd. 1Q 2024 Business Update Presentation Slides
Keppel Ltd. 1Q 2024 Business Update  Presentation SlidesKeppel Ltd. 1Q 2024 Business Update  Presentation Slides
Keppel Ltd. 1Q 2024 Business Update Presentation SlidesKeppelCorporation
 
Market Sizes Sample Report - 2024 Edition
Market Sizes Sample Report - 2024 EditionMarket Sizes Sample Report - 2024 Edition
Market Sizes Sample Report - 2024 EditionMintel Group
 
Case study on tata clothing brand zudio in detail
Case study on tata clothing brand zudio in detailCase study on tata clothing brand zudio in detail
Case study on tata clothing brand zudio in detailAriel592675
 
Call Girls In Connaught Place Delhi ❤️88604**77959_Russian 100% Genuine Escor...
Call Girls In Connaught Place Delhi ❤️88604**77959_Russian 100% Genuine Escor...Call Girls In Connaught Place Delhi ❤️88604**77959_Russian 100% Genuine Escor...
Call Girls In Connaught Place Delhi ❤️88604**77959_Russian 100% Genuine Escor...lizamodels9
 
Kenya Coconut Production Presentation by Dr. Lalith Perera
Kenya Coconut Production Presentation by Dr. Lalith PereraKenya Coconut Production Presentation by Dr. Lalith Perera
Kenya Coconut Production Presentation by Dr. Lalith Pereraictsugar
 
8447779800, Low rate Call girls in New Ashok Nagar Delhi NCR
8447779800, Low rate Call girls in New Ashok Nagar Delhi NCR8447779800, Low rate Call girls in New Ashok Nagar Delhi NCR
8447779800, Low rate Call girls in New Ashok Nagar Delhi NCRashishs7044
 
Investment in The Coconut Industry by Nancy Cheruiyot
Investment in The Coconut Industry by Nancy CheruiyotInvestment in The Coconut Industry by Nancy Cheruiyot
Investment in The Coconut Industry by Nancy Cheruiyotictsugar
 

Recently uploaded (20)

Future Of Sample Report 2024 | Redacted Version
Future Of Sample Report 2024 | Redacted VersionFuture Of Sample Report 2024 | Redacted Version
Future Of Sample Report 2024 | Redacted Version
 
/:Call Girls In Indirapuram Ghaziabad ➥9990211544 Independent Best Escorts In...
/:Call Girls In Indirapuram Ghaziabad ➥9990211544 Independent Best Escorts In.../:Call Girls In Indirapuram Ghaziabad ➥9990211544 Independent Best Escorts In...
/:Call Girls In Indirapuram Ghaziabad ➥9990211544 Independent Best Escorts In...
 
Call Girls In Radisson Blu Hotel New Delhi Paschim Vihar ❤️8860477959 Escorts...
Call Girls In Radisson Blu Hotel New Delhi Paschim Vihar ❤️8860477959 Escorts...Call Girls In Radisson Blu Hotel New Delhi Paschim Vihar ❤️8860477959 Escorts...
Call Girls In Radisson Blu Hotel New Delhi Paschim Vihar ❤️8860477959 Escorts...
 
8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR
8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR
8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR
 
FULL ENJOY Call girls in Paharganj Delhi | 8377087607
FULL ENJOY Call girls in Paharganj Delhi | 8377087607FULL ENJOY Call girls in Paharganj Delhi | 8377087607
FULL ENJOY Call girls in Paharganj Delhi | 8377087607
 
Youth Involvement in an Innovative Coconut Value Chain by Mwalimu Menza
Youth Involvement in an Innovative Coconut Value Chain by Mwalimu MenzaYouth Involvement in an Innovative Coconut Value Chain by Mwalimu Menza
Youth Involvement in an Innovative Coconut Value Chain by Mwalimu Menza
 
8447779800, Low rate Call girls in Shivaji Enclave Delhi NCR
8447779800, Low rate Call girls in Shivaji Enclave Delhi NCR8447779800, Low rate Call girls in Shivaji Enclave Delhi NCR
8447779800, Low rate Call girls in Shivaji Enclave Delhi NCR
 
NewBase 19 April 2024 Energy News issue - 1717 by Khaled Al Awadi.pdf
NewBase  19 April  2024  Energy News issue - 1717 by Khaled Al Awadi.pdfNewBase  19 April  2024  Energy News issue - 1717 by Khaled Al Awadi.pdf
NewBase 19 April 2024 Energy News issue - 1717 by Khaled Al Awadi.pdf
 
Call US-88OO1O2216 Call Girls In Mahipalpur Female Escort Service
Call US-88OO1O2216 Call Girls In Mahipalpur Female Escort ServiceCall US-88OO1O2216 Call Girls In Mahipalpur Female Escort Service
Call US-88OO1O2216 Call Girls In Mahipalpur Female Escort Service
 
BEST Call Girls In Old Faridabad ✨ 9773824855 ✨ Escorts Service In Delhi Ncr,
BEST Call Girls In Old Faridabad ✨ 9773824855 ✨ Escorts Service In Delhi Ncr,BEST Call Girls In Old Faridabad ✨ 9773824855 ✨ Escorts Service In Delhi Ncr,
BEST Call Girls In Old Faridabad ✨ 9773824855 ✨ Escorts Service In Delhi Ncr,
 
Contemporary Economic Issues Facing the Filipino Entrepreneur (1).pptx
Contemporary Economic Issues Facing the Filipino Entrepreneur (1).pptxContemporary Economic Issues Facing the Filipino Entrepreneur (1).pptx
Contemporary Economic Issues Facing the Filipino Entrepreneur (1).pptx
 
Buy gmail accounts.pdf Buy Old Gmail Accounts
Buy gmail accounts.pdf Buy Old Gmail AccountsBuy gmail accounts.pdf Buy Old Gmail Accounts
Buy gmail accounts.pdf Buy Old Gmail Accounts
 
Keppel Ltd. 1Q 2024 Business Update Presentation Slides
Keppel Ltd. 1Q 2024 Business Update  Presentation SlidesKeppel Ltd. 1Q 2024 Business Update  Presentation Slides
Keppel Ltd. 1Q 2024 Business Update Presentation Slides
 
Market Sizes Sample Report - 2024 Edition
Market Sizes Sample Report - 2024 EditionMarket Sizes Sample Report - 2024 Edition
Market Sizes Sample Report - 2024 Edition
 
Case study on tata clothing brand zudio in detail
Case study on tata clothing brand zudio in detailCase study on tata clothing brand zudio in detail
Case study on tata clothing brand zudio in detail
 
Call Girls In Connaught Place Delhi ❤️88604**77959_Russian 100% Genuine Escor...
Call Girls In Connaught Place Delhi ❤️88604**77959_Russian 100% Genuine Escor...Call Girls In Connaught Place Delhi ❤️88604**77959_Russian 100% Genuine Escor...
Call Girls In Connaught Place Delhi ❤️88604**77959_Russian 100% Genuine Escor...
 
Japan IT Week 2024 Brochure by 47Billion (English)
Japan IT Week 2024 Brochure by 47Billion (English)Japan IT Week 2024 Brochure by 47Billion (English)
Japan IT Week 2024 Brochure by 47Billion (English)
 
Kenya Coconut Production Presentation by Dr. Lalith Perera
Kenya Coconut Production Presentation by Dr. Lalith PereraKenya Coconut Production Presentation by Dr. Lalith Perera
Kenya Coconut Production Presentation by Dr. Lalith Perera
 
8447779800, Low rate Call girls in New Ashok Nagar Delhi NCR
8447779800, Low rate Call girls in New Ashok Nagar Delhi NCR8447779800, Low rate Call girls in New Ashok Nagar Delhi NCR
8447779800, Low rate Call girls in New Ashok Nagar Delhi NCR
 
Investment in The Coconut Industry by Nancy Cheruiyot
Investment in The Coconut Industry by Nancy CheruiyotInvestment in The Coconut Industry by Nancy Cheruiyot
Investment in The Coconut Industry by Nancy Cheruiyot
 

Real-Time Data. Real-World Impact.

  • 1. REAL-TIME REAL-WORLD SEE THE REAL-WORLD IMPACT FOR YOURSELF. WE DON’T JUST TALK ABOUT DATA. WE SHOW RESULTS.
  • 2. A DIRECT CONNECTION TO FINDING POTENTIAL CLINICAL TRIAL PARTICIPANTS CLIENT CHALLENGE CLIENT CHALLENGE REAL-WORLD IMPACT REAL-WORLD IMPACT Month 1 Results: 4,829 patients emailed, 523 visited the study website, 7 consented, 6 completed Patient Service Center (PSC) blood draws Difficulty recruiting patients for a virtual study with a PSC blood draw Extremely tight turnaround times for launching email campaigns and boosting recruitment PROTOCOL DESIGN TO MAXIMIZE PATIENT ENROLLMENT OPPORTUNITY Result: The eligible patient population increased by +50% without compromising the objectives of the trial. Analyzed LabCorp de-identified clinical laboratory data to discern whether small protocol changes could accelerate recruitment. Data helped to identify that making minor changes to the eGFR cutoff would increase the patient pool size, therefore reducing recruitment timelines. Study to test if a drug reduced progression of kidney disease in patients with Type II diabetes Study was looking for a small subset of patients which represented <7% of patients Leveraged LabCorp database to find potential patients in key geographies as specified by the client. LabCorp sent emails with study specific website links to targeted patient populations. Seeking patients with a history of stroke or cardiovascular event ~150 Million Lives >150 million patients >30 billion test results >
  • 3. INCORPORATING THE PATIENT VOICE CLIENT CHALLENGE CLIENT CHALLENGE REAL-WORLD IMPACT REAL-WORLD IMPACT Result: Conducted research with 320 Ulcerative Colitis patients to design a study to meet the client’s needs. Extended the known investigator database for Ulcerative Colitis with available capacity. Leveraged Covance Patient Intelligence Database to improve patient recruitment and retention rates. Identified investigator best- suited to run Ulcerative Colitis studies with available capacity. Limited patient population due to competing studies and the fact that 90% of patients don’t participate in clinical trials Difficulty finding, productive investigators for study in a highly competitive space EXCEEDING RECRUITMENT GOALS FOR A GLOBAL MULTI-STUDY REGISTRATION PROGRAM Result: Achieved “first patient in” (FPI) requirement ahead of schedule for all studies in the program. Beat historical industry performance across a number of key metrics: 18% fewer weeks from final protocol to FPI | 75% more high-performing sites 31% more patients/site/month | 41% fewer non-performing sites Randomize 2,700 patients within a very narrow timeframe for a suite of registration studies Get all sites across the globe up and running as quickly as possible Leveraged Xcellerate® historical investigator database to identify and secure highest performing investigators in indication. Based on extensive feasibility outreach and site capacity assessment, efficiencies were identified that allowed effective overlapping of sites across the program resulting in accelerated site start-up and reduced clinical costs. 90% ~30countries >20 indications >175k unique investigators >15k protocols
  • 4. *Average time savings based on an analysis of trials processed through Covance Central Labs with Protocol Finalization date after 1/1/2009 for the specific clinical indications. Past performance is not a guarantee of future results, and a variety of factors other than CRO performance can impact timing of clinical studies. Covance is the drug, medical device and diagnostics business segment of LabCorp, a leading global life sciences company. COVANCE is a registered trademark and the marketing name for Covance Inc. and its subsidiaries around the world. The Americas +1.888.COVANCE (+1.888.268.2623) +1.609.452.4440 Europe/Africa +00.800.2682.2682 +44.1423.500888 Asia Pacific +800.6568.3000 +65.6.5686588 © Copyright 2019 Covance Inc. BROCVD018-1019 REAL-TIME DATA. REAL-WORLD IMPACT. Talk to a representative to find out how Covance can impact your studies. LEARN MORE AT COVANCE.COM/REALIMPACT COVANCE DATA CAN HELP ACCELERATE YOUR STUDIES. Covance data is comprised of four powerful data sets: LabCorp De-Identified Lab Result Data, Covance Central Labs Investigator Data, Patient Direct and Patient Intelligence. The combination of these data sets provides unique insights, enabling us to deliver strong, viable protocol designs for faster patient enrollment, more patients per site and fewer non-performing sites than the industry average. By increasing forecast accuracy, you can minimize study costs and speed time to market. SITE ACTIVATION TO LAST PATIENT IN Number of Months* MONTHS FASTER CARDIOVASCULAR3.1 MARKET 12.92 MONTHS COVANCE 9.85 MONTHS 5.0 MARKET 14.88 MONTHS COVANCE 9.94 MONTHS MONTHS FASTER NEUROLOGY 3.3 MARKET 18.66 MONTHS COVANCE 15.41 MONTHS MONTHS FASTER HEMATOLOGY 4.2 MARKET 20.99 MONTHS COVANCE 16.80 MONTHS MONTHS FASTER ONCOLOGY